Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Non-Current Deferred Tax Liability (2017 - 2023)

Historic Non-Current Deferred Tax Liability for Aclaris Therapeutics (ACRS) over the last 7 years, with Q3 2023 value amounting to $367000.0.

  • Aclaris Therapeutics' Non-Current Deferred Tax Liability changed 0.0% to $367000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $367000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $367000.0 for FY2022, which is 0.0% changed from last year.
  • Latest data reveals that Aclaris Therapeutics reported Non-Current Deferred Tax Liability of $367000.0 as of Q3 2023, which was down 0.0% from $367000.0 recorded in Q2 2023.
  • In the past 5 years, Aclaris Therapeutics' Non-Current Deferred Tax Liability ranged from a high of $549000.0 in Q1 2019 and a low of $367000.0 during Q4 2020
  • Moreover, its 5-year median value for Non-Current Deferred Tax Liability was $367000.0 (2020), whereas its average is $434052.6.
  • Its Non-Current Deferred Tax Liability has fluctuated over the past 5 years, first changed by 0.0% in 2019, then tumbled by 3315.12% in 2020.
  • Quarter analysis of 5 years shows Aclaris Therapeutics' Non-Current Deferred Tax Liability stood at $549000.0 in 2019, then tumbled by 33.15% to $367000.0 in 2020, then changed by 0.0% to $367000.0 in 2021, then changed by 0.0% to $367000.0 in 2022, then changed by 0.0% to $367000.0 in 2023.
  • Its last three reported values are $367000.0 in Q3 2023, $367000.0 for Q2 2023, and $367000.0 during Q1 2023.